Routine cyclosporine concentration - C2 level monitoring. Is it helpful during the early post transplant period?

Medical Journal Armed Forces India

Volumn 60, Issue 4, 2004, Pages 326-328

  Narula, A S ^a   Murthy, M S N ^b   Patrulu, K S K ^c   Saxena, V K ^b  

^a ARMED FORCES MEDICAL COLLEGE   (India)

^b INHS Kasturi ^*

^c Southern Naval Command   (Japan)

Author keywords

C2 levels; Cyclosporine levels; Cyclosporine trough levels

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DEXAMETHASONE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PANIMMUNE; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAINTENANCE DRUG DOSE; MALE; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

EID: 17844396458     PISSN: 03771237     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0377-1237(04)80003-0     Document Type: Article

References (9)

1. Rao M, Iman A, Jacob CK. Event related Cyclosporine monitoring: Pitfalls in practice. Indian J Nephrology 2001;11:17-24.
2. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Its relationship to acute rejections and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999;68:55-62.
3. Belitsky P, Dunn S, Johnston A, Levy GA. Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients. Clin Pharmacokinet 2000;2:117-25.
4. Belitsky P, Levy GA, Johnston A. Neoral absorption profiling: An evolution in effectiveness. Transplantation Proceedings. 32:45 S-52 S.
5. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine, trough levels versus 2-hour post dose levels in stable liver transplant patients. Transplantation 66:1621-7.
6. Meyer MM, Munar M, Udeaja J, Bennet W. Efficacy of area under the curve monitoring in renal transplant recipients. J Am Soc Nephrol 1993;4:1306-9.
7. Belitsky P. Neoral use in the renal transplant recipient. Transplant Proceedings;32:10 S-19 S.
8. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998;12:243-6.
9. Baramma AA, Yilmaz S, Gough J, Belitsky P. Lower cyclosporine exposure increases the risk for sub clinical rejection in renal transplant recipients (abstract). Transplantation 2000;69:S 225.